Literature DB >> 12665523

Telomerase expression in normal human fibroblasts stabilizes DNA 5-methylcytosine transferase I.

Juan I Young1, John M Sedivy, James R Smith.   

Abstract

The finite proliferative potential of normal human fibroblasts can be overcome, a process commonly called immortalization, by the introduction of the catalytic subunit of human telomerase. In contrast to malignant transformation, the pattern of gene expression remains largely unmodified in telomerase-induced immortalization. Here we show evidence that suggests that the maintenance of a "young" pattern of gene expression by telomerization is mediated, at least in part, by a novel function of human telomerase that involves regulation of DNA methyltransferase I gene expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12665523     DOI: 10.1074/jbc.M301685200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Theoretical study of the interaction between 5-methylcytosine and acrylamide.

Authors:  Bo Na; Lihui Zhao; Zhicheng Liu
Journal:  J Mol Model       Date:  2012-05-17       Impact factor: 1.810

Review 2.  Chromatin maintenance and dynamics in senescence: a spotlight on SAHF formation and the epigenome of senescent cells.

Authors:  Armelle Corpet; Manuel Stucki
Journal:  Chromosoma       Date:  2014-05-27       Impact factor: 4.316

3.  Experimental manipulation of telomere length: does it reveal a corner-stone role for telomerase in the natural variability of individual fitness?

Authors:  F Criscuolo; S Smith; S Zahn; B J Heidinger; M F Haussmann
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-03-05       Impact factor: 6.237

4.  Telomerase deficiency in bone marrow-derived cells attenuates angiotensin II-induced abdominal aortic aneurysm formation.

Authors:  Hannes M Findeisen; Florence Gizard; Yue Zhao; Dianne Cohn; Elizabeth B Heywood; Karrie L Jones; David H Lovett; Deborah A Howatt; Alan Daugherty; Dennis Bruemmer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-18       Impact factor: 8.311

5.  Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT.

Authors:  Alexander Röth; Gabriela M Baerlocher; Mike Schertzer; Elizabeth Chavez; Ulrich Dührsen; Peter M Lansdorp
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

Review 6.  Nutrition in early life, and risk of cancer and metabolic disease: alternative endings in an epigenetic tale?

Authors:  Graham C Burdge; Karen A Lillycrop; Alan A Jackson
Journal:  Br J Nutr       Date:  2008-12-12       Impact factor: 3.718

7.  Differential expression of epigenetic modulators during human embryonic stem cell differentiation.

Authors:  Sharla M O Phipps; William K Love; Troy E Mott; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Mol Biotechnol       Date:  2008-10-25       Impact factor: 2.695

8.  [Enhanced control of proliferation in telomerized cells].

Authors:  E E Egorov; M V Moldaver; Kh S Vishniakova; S M Terekhov; E B Dashinimaev; I B Cheglakov; I Iu Toropygin; K N Iarygin; P M Chumakov; L I Korochkin; G A Antonova; E Iu Rybalkina; I N Saburina; N S Burnaevskiĭ; A V Zelenin
Journal:  Ontogenez       Date:  2007 Mar-Apr

9.  Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.

Authors:  Sivakumar Vijayaraghavalu; Josephine Kamtai Dermawan; Venugopalan Cheriyath; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2012-12-24       Impact factor: 4.939

10.  Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells.

Authors:  Nuri Ozturk; Esra Erdal; Mine Mumcuoglu; Kamil C Akcali; Ozden Yalcin; Serif Senturk; Ayca Arslan-Ergul; Bala Gur; Isik Yulug; Rengul Cetin-Atalay; Cengiz Yakicier; Tamer Yagci; Mesut Tez; Mehmet Ozturk
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.